Putative biomarkers and therapeutic targets associated with radiation resistance

Expert Review of Proteomics

Volumn 11, Issue 2, 2014, Pages 207-214

  Skvortsov, Sergej ^a   Debbage, Paul ^a   Cho, William C S ^b   Lukas, Peter ^a   Skvortsova, Ira ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

biomarker; cancer stem cells; intracellular signaling; proteomics; radiation therapy

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHAPERONIN 60; CYCLOPHILIN A; DEOXYRIBONUCLEASE I; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; NUCLEOSIDE DIPHOSPHATE KINASE A; RAC1 PROTEIN; REDOX FACTOR 1 APURINIC APYRIMIDINIC ENDONUCLEASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; HEAT SHOCK PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PROTEOME; RAC1 PROTEIN, HUMAN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOMA CELL; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL PROTECTION; CELL SURFACE; CELLULAR DISTRIBUTION; COLONY FORMATION; COLORECTAL CANCER; CYTOSKELETON; DIET SUPPLEMENTATION; DNA REPAIR; ENDOCYTOSIS; HEAD AND NECK CARCINOMA; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; IONIZING RADIATION; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MICROTUBULE ASSEMBLY; PHENOTYPE; PROSTATE CARCINOMA; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; OXIDATION REDUCTION REACTION; PROTEIN MICROARRAY; RADIATION DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; OXIDATION-REDUCTION; PROTEIN ARRAY ANALYSIS; PROTEOME; RAC1 GTP-BINDING PROTEIN; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896942587     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.893194     Document Type: Review

References (54)

1. Panis C, Pizzatti L, Abdelhay E. How can Proteomics Reach Cancer Biomarkers? Curr Proteomics 2013;10:136-49
2. Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J 2013;4:2
3. Smith L, Qutob O, Watson MB, et al. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia 2009;11:1194-207
4. Skvortsova I, Skvortsov S, Stasyk T, et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008;8:4521-33
5. Skvortsov S, Jimenez CR, Knol JC, et al. Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol 2011;101:177-82
6. Kranenburg O, Emmink BL, Knol J, et al. Proteomics in studying cancer stem cell biology. Expert Rev Proteomics 2012;9: 325-36
7. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17: 313-19
8. Zhang B, Qu JQ, Xiao L, et al. Identification of heat shock protein 27 as a radioresistance-related protein in nasopharyngeal carcinoma cells. J Cancer Res Clin Oncol 2012;138:2117-25
9. Lin TY, Chang JT, Wang HM, et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:246-56
10. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res 2006;47:183-96
11. Feng XP, Yi H, Li MY, et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 2010;70:3450-62
12. Svendsen A, Verhoeff JJ, Immervoll H, et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 2011;122: 495-510
13. Chevalier F, Depagne J, Hem S, et al. Accumulation of cyclophilin A isoforms in conditioned medium of irradiated breast cancer cells. Proteomics 2012;12: 1756-66
14. Wu P, Zhang H, Qi L, et al. Identification of ERp29 as a biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Oncol Rep 2012;27:987-94
15. Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol 2013;87:19-48
16. Nagaraja GM, Kaur P, Asea A. Role of human and mouse HspB1 in metastasis. Curr Mol Med 2012;12:1142-50
17. Wei L, Liu TT, Wang HH, et al. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappaB. Breast Cancer Res 2011;13:R101
18. Fu J, Koul D, Yao J, et al. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res 2013;73:3062-74
19. Gray PC, Vale W. Cripto/ GRP78 modulation of the TGF-beta pathway in development and oncogenesis. FEBS Lett 2012;586:1836-45
20. Wu MJ, Jan CI, Tsay YG, et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer 2010;9:283
21. Hamelin C, Cornut E, Poirier F, et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J 2011;278:4845-59
22. Sato Y, Harada K, Sasaki M, et al. Heat shock proteins 27 and 70 are potential biliary markers for the detection of cholangiocarcinoma. Am J Pathol 2012;180: 123-30
23. Lee E, Nichols P, Groshen S, et al. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 2011;128:726-31
24. Wang K, Zhang T, Dong Q, et al. Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis 2013;4:e537
25. Kim MH, Kim HB, Yoon SP, et al. Colon cancer progression is driven by APEX1-mediated upregulation of Jagged. J Clin Invest 2013;123(8):3211-30
26. Minisini AM, Di LC, Mansutti M, et al. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett 2005;224: 133-9
27. Prabhu VV, Siddikuzzaman Grace VM, Guruvayoorappan C. Targeting tumor metastasis by regulating Nm23 gene expression. Asian Pac J Cancer Prev 2012;13:3539-48
28. Almgren MA, Henriksson KC, Fujimoto J, Chang CL. Nucleoside diphosphate kinase A/nm23-H1 promotes metastasis of NB69-derived human neuroblastoma. Mol Cancer Res 2004;2:387-94
29. Kim SH, Lee SY, Park HR, et al. Nuclear localization of Nm23-H1 in head and neck squamous cell carcinoma is associated with radiation resistance. Cancer 2011;117: 1864-73
30. Yoon CH, Hyun KH, Kim RK, et al. The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells. FEBS Lett 2011;585:2331-8
31. Koh MS, Moon A. Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells. Biochem Biophys Res Commun 2011;406: 25-9
32. Ma Q, Cavallin LE, Yan B, et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci USA 2009;106:8683-8
33. Iwashima F, Yoshimoto T, Minami I, et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008;149:1009-14
34. Gastonguay A, Berg T, Hauser AD, et al. The role of Rac1 in the regulation of NF-kappaB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 2012;13: 647-56
35. Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One 2011;6:e16951
36. Li XR, Ji F, Ouyang J, et al. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol 2006;32:1130-4
37. Benitah SA, Valeron PF, van Aelst L, et al. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004;1705:121-32
38. Mendoza-Catalan MA, Cristobal-Mondragon GR, me-Gomez J, et al. Nuclear expression of Rac1 in cervical premalignant lesions and cervical cancer cells. BMC Cancer 2012;12:116
39. Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009;8:1557-69
40. Tilghman SL, Townley I, Zhong Q, et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics 2013;12(9):2440-55
41. Jeong HG, Cho HJ, Chang IY, et al. Rac1 prevents cisplatin-induced apoptosis through down-regulation of p38 activation in NIH3T3 cells. FEBS Lett 2002;518: 129-34
42. Kato T, Fujita Y, Nakane K, et al. CCR1/ CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine 2013;64(1):251-7
43. Chen SF, Nieh S, Jao SW, et al. Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS One 2012;7:e49275
44. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett 2013;23:1923-8
45. Ischia J, Saad F, Gleave M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol 2013;23:194-200
46. Schilling D, Bayer C, Li W, et al. Radiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1alpha. PLoS One 2012;7:e31110
47. Musha A, Yoshida Y, Takahashi T, et al. Synergistic effect of heat shock protein inhibitor, 17-allylamino-17- demethoxygeldanamycin and X-rays, but not carbon-ion beams, on lethality in human oral squamous cell carcinoma cells. J Radiat Res 2012;53:545-50
48. Djuzenova CS, Blassl C, Roloff K, et al. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia. Cancer Biol Ther 2012;13: 425-34
49. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76
50. Kelley MR, Luo M, Reed A, et al. Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/ Ref-1. Antioxid Redox Signal 2011;14: 1387-401
51. Fishel ML, Jiang Y, Rajeshkumar NV, et al. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol Cancer Ther 2011;10:1698-708
52. Kelley M. DNA repair in cancer therapy: molecular targets and clinical applications. Elsevier, Inc; San Diego, CA, USA: 2012
53. Katz E, Sims AH, Sproul D, et al. Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 2012;3:608-19
54. Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013;9:86-98